Week in Review: China Resources Pharma Files for $369 Million China Life Science Investment Fund

Deals and Financings China Resources Pharma announced plans to raise $368.5 million for a China life science investment fund; Chi-Med (Hutchison China MediTech) completed a $301 million secondary offering of its US shares to support its drug development program; Maxhealth Medicine of Wuxi , China struck a deal with Switzerland 's Legacy Healthcare to commercialize Legacy's hair loss treatment in China ; Trials and Approvals Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine, which it developed with the Bioengineering Institute of the Chinese Academy of Military Medical Sciences; Suzhou 's MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of its second-generation PD-L1 antibody; Denovo Biopharma, a San Diego-Beijing company, announced approval to conduct a US arm of China-US Phase III trial for its lead lymphoma drug; Transgene reported its therapeutic hepatitis B vaccine was safe and promoted immunogenicity in a Phase I/Ib trial in Europe; the vaccine is expected to start China trials soon; BeyondSpring of New York enrolled the first patient in the China arm of a global Phase II/III clinical trial of plinabulin to prevent chemotherapy-induced neutropenia.  Stock Symbols: (HK: 3320) (AIM/NSDQ: HCM) (Euronext: TNG) (NSDQ: BYSI) Share this with colleagues: // //